;PMID: 10805063
;source_file_919.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..52] = [t:0..52]
;1)sentence:[e:58..192] = [t:58..192]
;2)section:[e:196..248] = [t:196..248]
;3)section:[e:252..345] = [t:252..345]
;4)sentence:[e:349..359] = [t:349..359]
;5)sentence:[e:360..444] = [t:360..444]
;6)sentence:[e:445..629] = [t:445..629]
;7)sentence:[e:630..914] = [t:630..914]
;8)sentence:[e:915..923] = [t:915..923]
;9)sentence:[e:924..1345] = [t:924..1345]
;10)sentence:[e:1347..1417] = [t:1347..1417]
;11)sentence:[e:1419..1504] = [t:1419..1504]
;12)sentence:[e:1505..1597] = [t:1505..1597]
;13)sentence:[e:1598..1655] = [t:1598..1655]
;14)sentence:[e:1657..1767] = [t:1657..1767]
;15)sentence:[e:1768..1850] = [t:1768..1850]
;16)sentence:[e:1851..1936] = [t:1851..1936]
;17)sentence:[e:1937..2131] = [t:1937..2131]
;18)sentence:[e:2132..2241] = [t:2132..2241]
;19)sentence:[e:2242..2254] = [t:2242..2254]
;20)sentence:[e:2255..2559] = [t:2255..2559]
;21)sentence:[e:2560..2695] = [t:2560..2695]
;22)section:[e:2699..2744] = [t:2699..2744]

;section 0 Span:0..52
;Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..10] Clin)
        (NNP:[11..20] Pharmacol) (.:[20..21] .) (CD:[22..26] 2000)
        (NNP:[27..30] Feb) (HYPH:[30..31] -) (CC:[31..38] Mar;55-LRB-)
        (CD:[38..40] 11) (HYPH:[40..41] -) (CD:[41..43] 12)
        (-RRB-:[43..44] -RRB-) (CD:[44..48] :843) (::[48..49] -)
        (CD:[49..51] 52) (.:[51..52] .)))

;sentence 1 Span:58..192
;Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium 
;antagonists: prediction of in vivo drug-drug interactions.
;[78..101]:cyp450:"cytochrome P450 enzymes"
;[105..124]:substance:"1,4-dihydropyridine"
;[125..132]:substance:"calcium"
;[134..145]:substance:"antagonists"
;[169..173]:substance:"drug"
;[174..178]:substance:"drug"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[58..68] Inhibition))
      (PP (IN:[69..71] of)
        (NP (JJ:[72..77] human)
          
          (NML (NN:[78..88] cytochrome) (NN:[89..93] P450))
          (NNS:[94..101] enzymes)))
      (PP (IN:[102..104] by)
        (NP (NN:[105..124] 1,4-dihydropyridine) (NN:[125..132] calcium)
            (NNS:[134..145] antagonists))))
    (::[145..146] :)
    (NP
      (NP (NN:[147..157] prediction))
      (PP (IN:[158..160] of)
        (NP
          (ADJP (FW:[161..163] in) (FW:[164..168] vivo))
          (NML (NN:[169..173] drug) (HYPH:[173..174] -) (NN:[174..178] drug))
          (NNS:[179..191] interactions))))
    (.:[191..192] .)))

;section 2 Span:196..248
;Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T.
(SEC
  (FRAG (NNP:[196..201] Katoh) (NNP:[202..204] M,) (NNP:[205..213] Nakajima)
        (NNP:[214..216] M,) (NNP:[217..224] Shimada) (NNP:[225..226] N)
        (,:[226..227] ,) (NNP:[228..236] Yamazaki) (NNP:[237..238] H)
        (,:[238..239] ,) (NNP:[240..245] Yokoi) (NNP:[246..248] T.)))

;section 3 Span:252..345
;Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa 
;University, Japan.
(SEC
  (FRAG (NNP:[252..260] Division) (IN:[261..263] of) (NNP:[264..268] Drug)
        (NNP:[269..279] Metabolism) (,:[279..280] ,) (NNP:[281..288] Faculty)
        (IN:[289..291] of) (NNP:[292..306] Pharmaceutical)
        (NNPS:[307..315] Sciences) (,:[315..316] ,) (NNP:[317..325] Kanazawa)
        (NNP:[327..337] University) (,:[337..338] ,) (NNP:[339..344] Japan)
        (.:[344..345] .)))

;sentence 4 Span:349..359
;OBJECTIVE:
(SENT
  (NP (NN:[349..358] OBJECTIVE) (::[358..359] :)))

;sentence 5 Span:360..444
;1,4-Dihydropyridine calcium antagonists such as nifedipine are potent 
;vasodilators.
;[360..379]:substance:"1,4-Dihydropyridine"
;[380..387]:substance:"calcium"
;[388..399]:substance:"antagonists"
;[408..418]:substance:"nifedipine"
;[431..443]:substance:"vasodilators"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[360..379] 1,4-Dihydropyridine) (NN:[380..387] calcium)
          (NNS:[388..399] antagonists))
      (PP (JJ:[400..404] such) (IN:[405..407] as)
        (NP (NN:[408..418] nifedipine))))
    (VP (VBP:[419..422] are)
      (NP-PRD (JJ:[423..429] potent) (NNS:[431..443] vasodilators)))
    (.:[443..444] .)))

;sentence 6 Span:445..629
;It is now commonly agreed that the oxidation of  1,4-dihydropyridine into
;pyridine, which is one of the main metabolic pathways,  is catalysed by the
;cytochrome P450 (CYP) 3A4 isoform.
;[494..513]:substance:"1,4-dihydropyridine"
;[519..527]:substance:"pyridine"
;[595..628]:cyp450:"cytochrome P450 (CYP) 3A4 isoform"
(SENT
  (S
    (NP-SBJ-4
      (NP (PRP:[445..447] It))
      (SBAR-3 (-NONE-:[447..447] *EXP*)))
    (VP (VBZ:[448..450] is)
      (ADVP-TMP (RB:[451..454] now))
      (ADVP (RB:[455..463] commonly))
      (VP (VBN:[464..470] agreed)
        (NP-4 (-NONE-:[470..470] *))
        (SBAR-3 (IN:[471..475] that)
          (S
            (NP-SBJ-2
              (NP (DT:[476..479] the) (NN:[480..489] oxidation))
              (PP (IN:[490..492] of)
                (NP (NN:[494..513] 1,4-dihydropyridine)))
              (PP (IN:[514..518] into)
                (NP
                  (NP (NN:[519..527] pyridine))
                  (,:[527..528] ,)
                  (SBAR
                    (WHNP-1 (WDT:[529..534] which))
                    (S
                      (NP-SBJ-1 (-NONE-:[534..534] *T*))
                      (VP (VBZ:[535..537] is)
                        (NP-PRD
                          (NP (CD:[538..541] one))
                          (PP (IN:[542..544] of)
                            (NP (DT:[545..548] the) (JJ:[549..553] main)
                                (JJ:[554..563] metabolic)
                                (NNS:[564..572] pathways))))))))))
            (,:[572..573] ,)
            (VP (VBZ:[575..577] is)
              (VP (VBN:[578..587] catalysed)
                (NP-2 (-NONE-:[587..587] *))
                (PP (IN:[588..590] by)
                  (NP-LGS (DT:[591..594] the)
                    
                    (NML
                      (NML (NN:[595..605] cytochrome) (NN:[606..610] P450))
                      (NML (-LRB-:[611..612] -LRB-) (NN:[612..615] CYP)
                           (-RRB-:[615..616] -RRB-)))
                    (NN:[617..620] 3A4) (NN:[621..628] isoform)))))))))
    (.:[628..629] .)))

;sentence 7 Span:630..914
;In the present study, the  inhibitory effects of 13 kinds of
;1,4-dihydropyridine calcium antagonists  clinically used in Japan on human
;CYP-isoform-dependent reactions were  investigated to predict the drug
;interactions using microsomes from human  B-lymphoblast cells expressing
;CYP.
;[691..710]:substance:"1,4-dihydropyridine"
;[711..718]:substance:"calcium"
;[719..730]:substance:"antagonists"
;[766..777]:cyp450:"CYP-isoform"
;[832..836]:substance:"drug"
;[910..913]:cyp450:"CYP"
(SENT
  (S
    (PP-LOC (IN:[630..632] In)
      (NP (DT:[633..636] the) (JJ:[637..644] present) (NN:[645..650] study)))
    (,:[650..651] ,)
    (NP-SBJ-1
      (NP (DT:[652..655] the) (JJ:[657..667] inhibitory)
          (NNS:[668..675] effects))
      (PP (IN:[676..678] of)
        (NP
          (NP (CD:[679..681] 13) (NNS:[682..687] kinds))
          (PP (IN:[688..690] of)
            (NP
              (NP (NN:[691..710] 1,4-dihydropyridine) (NN:[711..718] calcium)
                  (NNS:[719..730] antagonists))
              (VP
                (ADVP (RB:[732..742] clinically))
                (VBN:[743..747] used)
                (NP (-NONE-:[747..747] *))
                (PP-LOC (IN:[748..750] in)
                  (NP (NNP:[751..756] Japan))))))))
      (PP (IN:[757..759] on)
        (NP (JJ:[760..765] human)
          (ADJP
            (NML (NN:[766..769] CYP) (HYPH:[769..770] -) (NN:[770..777] isoform))
            (HYPH:[777..778] -) (JJ:[778..787] dependent))
          (NNS:[788..797] reactions))))
    (VP (VBD:[798..802] were)
      (VP (VBN:[804..816] investigated)
        (NP-1 (-NONE-:[816..816] *))
        (S-PRP
          (NP-SBJ (-NONE-:[816..816] *))
          (VP (TO:[817..819] to)
            (VP (VB:[820..827] predict)
              (NP (DT:[828..831] the) (NN:[832..836] drug)
                  (NNS:[837..849] interactions)))))
        (S-MNR
          (NP-SBJ (-NONE-:[849..849] *))
          (VP (VBG:[850..855] using)
            (NP
              (NP (NNS:[856..866] microsomes))
              (PP (IN:[867..871] from)
                (NP
                  (NP (JJ:[872..877] human) (NN:[879..892] B-lymphoblast)
                      (NNS:[893..898] cells))
                  (VP (VBG:[899..909] expressing)
                    (NP (NN:[910..913] CYP))))))))))
    (.:[913..914] .)))

;sentence 8 Span:915..923
;RESULTS:
(SENT
  (NP (NNS:[915..922] RESULTS) (::[922..923] :)))

;sentence 9 Span:924..1345
;The specific activities for human  CYP isoforms included 7-ethoxyresorfin
;O-deethylation (CYP1A1), phenacetin  O-deethylation (CYP1A2), coumarin
;7-hydroxylation (CYP2A6), 7-benzyloxyresorufin  O-dealkylation (CYP2B6),
;S-warfarin 7-hydroxylation (CYP2C9), S-mephenytoin  4'-hydroxylaion
;(CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), chlorzoxazone 
;6-hydroxylation (CYP2E1), and testosterone 6beta-hydroxylation (CYP3A4).
;[959..971]:cyp450:"CYP isoforms"
;[981..997]:substance:"7-ethoxyresorfin"
;[1014..1020]:cyp450:"CYP1A1"
;[1023..1033]:substance:"phenacetin"
;[1051..1057]:cyp450:"CYP1A2"
;[1060..1068]:substance:"coumarin"
;[1086..1092]:cyp450:"CYP2A6"
;[1095..1115]:substance:"7-benzyloxyresorufin"
;[1133..1139]:cyp450:"CYP2B6"
;[1142..1152]:substance:"S-warfarin"
;[1170..1176]:cyp450:"CYP2C9"
;[1179..1192]:substance:"S-mephenytoin"
;[1211..1218]:cyp450:"CYP2C19"
;[1221..1230]:substance:"bufuralol"
;[1249..1255]:cyp450:"CYP2D6"
;[1258..1271]:substance:"chlorzoxazone"
;[1290..1296]:cyp450:"CYP2E1"
;[1303..1315]:substance:"testosterone"
;[1337..1343]:cyp450:"CYP3A4"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[924..927] The) (JJ:[928..936] specific)
          (NNS:[937..947] activities))
      (PP (IN:[948..951] for)
        (NP (JJ:[952..957] human)
           (NN:[959..962] CYP) (NNS:[963..971] isoforms))))
    (VP (VBD:[972..980] included)
      (NP
        (NP
          (NP (NN:[981..997] 7-ethoxyresorfin) (NN:[998..1012] O-deethylation))
          (NP (-LRB-:[1013..1014] -LRB-) (NN:[1014..1020] CYP1A1)
              (-RRB-:[1020..1021] -RRB-)))
        (,:[1021..1022] ,)
        (NP
          (NP (NN:[1023..1033] phenacetin) (NN:[1035..1049] O-deethylation))
          (NP (-LRB-:[1050..1051] -LRB-) (NN:[1051..1057] CYP1A2)
              (-RRB-:[1057..1058] -RRB-)))
        (,:[1058..1059] ,)
        (NP
          (NP (NN:[1060..1068] coumarin) (NN:[1069..1084] 7-hydroxylation))
          (NP (-LRB-:[1085..1086] -LRB-) (NN:[1086..1092] CYP2A6)
              (-RRB-:[1092..1093] -RRB-)))
        (,:[1093..1094] ,)
        (NP
          (NP (NN:[1095..1115] 7-benzyloxyresorufin)
              (NN:[1117..1131] O-dealkylation))
          (NP (-LRB-:[1132..1133] -LRB-) (NN:[1133..1139] CYP2B6)
              (-RRB-:[1139..1140] -RRB-)))
        (,:[1140..1141] ,)
        (NP
          (NP (NN:[1142..1152] S-warfarin) (NN:[1153..1168] 7-hydroxylation))
          (NP (-LRB-:[1169..1170] -LRB-) (NN:[1170..1176] CYP2C9)
              (-RRB-:[1176..1177] -RRB-)))
        (,:[1177..1178] ,)
        (NP
          (NP (NN:[1179..1192] S-mephenytoin) (NN:[1194..1209] 4'-hydroxylaion))
          (NP (-LRB-:[1210..1211] -LRB-) (NN:[1211..1218] CYP2C19)
              (-RRB-:[1218..1219] -RRB-)))
        (,:[1219..1220] ,)
        (NP
          (NP (NN:[1221..1230] bufuralol) (NN:[1231..1247] 1'-hydroxylation))
          (NP (-LRB-:[1248..1249] -LRB-) (NN:[1249..1255] CYP2D6)
              (-RRB-:[1255..1256] -RRB-)))
        (,:[1256..1257] ,)
        (NP
          (NP (NN:[1258..1271] chlorzoxazone) (NN:[1273..1288] 6-hydroxylation))
          (NP (-LRB-:[1289..1290] -LRB-) (NN:[1290..1296] CYP2E1)
              (-RRB-:[1296..1297] -RRB-)))
        (,:[1297..1298] ,) (CC:[1299..1302] and)
        (NP
          (NP (NN:[1303..1315] testosterone)
              (NN:[1316..1335] 6beta-hydroxylation))
          (NP (-LRB-:[1336..1337] -LRB-) (NN:[1337..1343] CYP3A4)
              (-RRB-:[1343..1344] -RRB-)))))
    (.:[1344..1345] .)))

;sentence 10 Span:1347..1417
;Benidipine and amlodipine competitively inhibited the CYP1A1 activity.
;[1347..1357]:substance:"Benidipine"
;[1362..1372]:substance:"amlodipine"
;[1401..1407]:cyp450:"CYP1A1"
(SENT
  (S
    (NP-SBJ (NN:[1347..1357] Benidipine) (CC:[1358..1361] and)
            (NN:[1362..1372] amlodipine))
    (ADVP (RB:[1373..1386] competitively))
    (VP (VBD:[1387..1396] inhibited)
      (NP (DT:[1397..1400] the) (NN:[1401..1407] CYP1A1)
          (NN:[1408..1416] activity)))
    (.:[1416..1417] .)))

;sentence 11 Span:1419..1504
;Nifedipine, nisoldipine and aranidipine competitively inhibited the CYP1A2 
;activity.
;[1419..1429]:substance:"Nifedipine"
;[1431..1442]:substance:"nisoldipine"
;[1447..1458]:substance:"aranidipine"
;[1487..1493]:cyp450:"CYP1A2"
(SENT
  (S
    (NP-SBJ (NN:[1419..1429] Nifedipine) (,:[1429..1430] ,)
            (NN:[1431..1442] nisoldipine) (CC:[1443..1446] and)
            (NN:[1447..1458] aranidipine))
    (ADVP (RB:[1459..1472] competitively))
    (VP (VBD:[1473..1482] inhibited)
      (NP (DT:[1483..1486] the) (NN:[1487..1493] CYP1A2)
          (NN:[1495..1503] activity)))
    (.:[1503..1504] .)))

;sentence 12 Span:1505..1597
;No 1,4-dihydropyridie calcium antagonists used in this study inhibited  the
;CYP2A6 activity.
;[1508..1526]:substance:"1,4-dihydropyridie"
;[1527..1534]:substance:"calcium"
;[1535..1546]:substance:"antagonists"
;[1581..1587]:cyp450:"CYP2A6"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1505..1507] No) (NN:[1508..1526] 1,4-dihydropyridie)
          (NN:[1527..1534] calcium) (NNS:[1535..1546] antagonists))
      (VP (VBN:[1547..1551] used)
        (NP (-NONE-:[1551..1551] *))
        (PP-LOC (IN:[1552..1554] in)
          (NP (DT:[1555..1559] this) (NN:[1560..1565] study)))))
    (VP (VBD:[1566..1575] inhibited)
      (NP (DT:[1577..1580] the) (NN:[1581..1587] CYP2A6)
          (NN:[1588..1596] activity)))
    (.:[1596..1597] .)))

;sentence 13 Span:1598..1655
;Barnidipine and amlodipine inhibited the CYP2B6 activity.
;[1598..1609]:substance:"Barnidipine"
;[1614..1624]:substance:"amlodipine"
;[1639..1645]:cyp450:"CYP2B6"
(SENT
  (S
    (NP-SBJ (NN:[1598..1609] Barnidipine) (CC:[1610..1613] and)
            (NN:[1614..1624] amlodipine))
    (VP (VBD:[1625..1634] inhibited)
      (NP (DT:[1635..1638] the) (NN:[1639..1645] CYP2B6)
          (NN:[1646..1654] activity)))
    (.:[1654..1655] .)))

;sentence 14 Span:1657..1767
;Nicardipine, benidipine, manidipine and barnidipine competitively inhibited
;the  CYP2C9 and CYP2D6 activities.
;[1657..1668]:substance:"Nicardipine"
;[1670..1680]:substance:"benidipine"
;[1682..1692]:substance:"manidipine"
;[1697..1708]:substance:"barnidipine"
;[1738..1744]:cyp450:"CYP2C9"
;[1749..1755]:cyp450:"CYP2D6"
(SENT
  (S
    (NP-SBJ (NN:[1657..1668] Nicardipine) (,:[1668..1669] ,)
            (NN:[1670..1680] benidipine) (,:[1680..1681] ,)
            (NN:[1682..1692] manidipine) (CC:[1693..1696] and)
            (NN:[1697..1708] barnidipine))
    (ADVP (RB:[1709..1722] competitively))
    (VP (VBD:[1723..1732] inhibited)
      (NP (DT:[1733..1736] the)
        (NML
          (NML (NN:[1738..1744] CYP2C9)
            (NML-1 (-NONE-:[1744..1744] *P*)))
          (CC:[1745..1748] and)
          (NML (NN:[1749..1755] CYP2D6)
            (NML-1 (NNS:[1756..1766] activities))))))
    (.:[1766..1767] .)))

;sentence 15 Span:1768..1850
;Inhibition extent of the CYP2E1 activity by  nifedipine and aranidipine were
;weak.
;[1793..1799]:cyp450:"CYP2E1"
;[1813..1823]:substance:"nifedipine"
;[1828..1839]:substance:"aranidipine"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1768..1778] Inhibition) (NN:[1779..1785] extent))
      (PP (IN:[1786..1788] of)
        (NP (DT:[1789..1792] the) (NN:[1793..1799] CYP2E1)
            (NN:[1800..1808] activity)))
      (PP (IN:[1809..1811] by)
        (NP (NN:[1813..1823] nifedipine) (CC:[1824..1827] and)
            (NN:[1828..1839] aranidipine))))
    (VP (VBD:[1840..1844] were)
      (ADJP-PRD (JJ:[1845..1849] weak)))
    (.:[1849..1850] .)))

;sentence 16 Span:1851..1936
;Nicardipine, benidipine and barnidipine  inhibited the CYP2C19 and CYP3A4
;activities.
;[1851..1862]:substance:"Nicardipine"
;[1864..1874]:substance:"benidipine"
;[1879..1890]:substance:"barnidipine"
;[1906..1913]:cyp450:"CYP2C19"
;[1918..1924]:cyp450:"CYP3A4"
(SENT
  (S
    (NP-SBJ (NN:[1851..1862] Nicardipine) (,:[1862..1863] ,)
            (NN:[1864..1874] benidipine) (CC:[1875..1878] and)
            (NN:[1879..1890] barnidipine))
    (VP (VBD:[1892..1901] inhibited)
      (NP (DT:[1902..1905] the)
        (NML
          (NML (NN:[1906..1913] CYP2C19)
            (NML-1 (-NONE-:[1913..1913] *P*)))
          (CC:[1914..1917] and)
          (NML (NN:[1918..1924] CYP3A4)
            (NML-1 (NNS:[1925..1935] activities))))))
    (.:[1935..1936] .)))

;sentence 17 Span:1937..2131
;Among the human CYP isoforms  investigated, the inhibitory effects of
;1,4-dihydropyridine calcium antagonists  were potent on human CYP1A2, CYP2B6,
;CYP2C9, CYP2C19 and CYP2D6 as well as  CYP3A4.
;[1953..1965]:cyp450:"CYP isoforms"
;[2007..2026]:substance:"1,4-dihydropyridine"
;[2027..2034]:substance:"calcium"
;[2035..2046]:substance:"antagonists"
;[2069..2075]:cyp450:"CYP1A2"
;[2077..2083]:cyp450:"CYP2B6"
;[2085..2091]:cyp450:"CYP2C9"
;[2093..2100]:cyp450:"CYP2C19"
;[2105..2111]:cyp450:"CYP2D6"
;[2124..2130]:cyp450:"CYP3A4"
(SENT
  (S
    (PP (IN:[1937..1942] Among)
      (NP
        (NP (DT:[1943..1946] the) (JJ:[1947..1952] human)
           (NN:[1953..1956] CYP) (NNS:[1957..1965] isoforms))
        (VP (VBN:[1967..1979] investigated)
          (NP (-NONE-:[1979..1979] *)))))
    (,:[1979..1980] ,)
    (NP-SBJ
      (NP (DT:[1981..1984] the) (JJ:[1985..1995] inhibitory)
          (NNS:[1996..2003] effects))
      (PP (IN:[2004..2006] of)
        (NP (NN:[2007..2026] 1,4-dihydropyridine) (NN:[2027..2034] calcium)
            (NNS:[2035..2046] antagonists))))
    (VP (VBD:[2048..2052] were)
      (ADJP-PRD (JJ:[2053..2059] potent))
      (PP-LOC (IN:[2060..2062] on)
        (NP
          (NP
            (ADJP-1 (JJ:[2063..2068] human))
            (NN:[2069..2075] CYP1A2))
          (,:[2075..2076] ,)
          (NP
            (ADJP-1 (-NONE-:[2076..2076] *P*))
            (NN:[2077..2083] CYP2B6))
          (,:[2083..2084] ,)
          (NP
            (ADJP-1 (-NONE-:[2084..2084] *P*))
            (NN:[2085..2091] CYP2C9))
          (,:[2091..2092] ,)
          (NP
            (ADJP-1 (-NONE-:[2092..2092] *P*))
            (NN:[2093..2100] CYP2C19))
          (CC:[2101..2104] and)
          (NP
            (ADJP-1 (-NONE-:[2104..2104] *P*))
            (NN:[2105..2111] CYP2D6))
          (CONJP (RB:[2112..2114] as) (RB:[2115..2119] well)
                 (IN:[2120..2122] as))
          (NP
            (ADJP-1 (-NONE-:[2122..2122] *P*))
            (NN:[2124..2130] CYP3A4)))))
    (.:[2130..2131] .)))

;sentence 18 Span:2132..2241
;Furthermore, the isoform selectivity of inhibition by  1,4-dihydropyridine
;calcium antagonists was clarified.
;[2149..2156]:substance:"isoform"
;[2187..2206]:substance:"1,4-dihydropyridine"
;[2207..2214]:substance:"calcium"
;[2215..2226]:substance:"antagonists"
(SENT
  (S
    (ADVP (RB:[2132..2143] Furthermore))
    (,:[2143..2144] ,)
    (NP-SBJ-1
      (NP (DT:[2145..2148] the) (NN:[2149..2156] isoform)
          (NN:[2157..2168] selectivity))
      (PP (IN:[2169..2171] of)
        (NP
          (NP (NN:[2172..2182] inhibition))
          (PP (IN:[2183..2185] by)
            (NP (NN:[2187..2206] 1,4-dihydropyridine) (NN:[2207..2214] calcium)
                (NNS:[2215..2226] antagonists))))))
    (VP (VBD:[2227..2230] was)
      (VP (VBN:[2231..2240] clarified)
        (NP-1 (-NONE-:[2240..2240] *))))
    (.:[2240..2241] .)))

;sentence 19 Span:2242..2254
;CONCLUSIONS:
(SENT
  (NP (NNS:[2242..2253] CONCLUSIONS) (::[2253..2254] :)))

;sentence 20 Span:2255..2559
;In  consideration of the Ki values obtained in the in vitro inhibition study
;and the  concentration of 1,4-dihydropyridine calcium antagonists in human
;liver, the  possibility of in vivo drug interactions of nicardipine and other
;drugs which  are mainly metabolised by CYP2C9 and/or CYP3A4 was suggested.
;[2280..2282]:quantitative-name:"Ki"
;[2358..2377]:substance:"1,4-dihydropyridine"
;[2378..2385]:substance:"calcium"
;[2386..2397]:substance:"antagonists"
;[2442..2446]:substance:"drug"
;[2463..2474]:substance:"nicardipine"
;[2485..2490]:substance:"drugs"
;[2524..2530]:cyp450:"CYP2C9"
;[2538..2544]:cyp450:"CYP3A4"
(SENT
  (S
    (PP (IN:[2255..2257] In)
      (NP
        (NP (NN:[2259..2272] consideration))
        (PP (IN:[2273..2275] of)
          (NP
            (NP
              (NP (DT:[2276..2279] the) (NN:[2280..2282] Ki)
                  (NNS:[2283..2289] values))
              (VP (VBN:[2290..2298] obtained)
                (NP (-NONE-:[2298..2298] *))
                (PP (IN:[2299..2301] in)
                  (NP (DT:[2302..2305] the)
                    (ADJP (FW:[2306..2308] in) (FW:[2309..2314] vitro))
                    (NN:[2315..2325] inhibition) (NN:[2326..2331] study)))))
            (CC:[2332..2335] and)
            (NP
              (NP (DT:[2336..2339] the) (NN:[2341..2354] concentration))
              (PP (IN:[2355..2357] of)
                (NP (NN:[2358..2377] 1,4-dihydropyridine)
                    (NN:[2378..2385] calcium) (NNS:[2386..2397] antagonists)))
              (PP-LOC (IN:[2398..2400] in)
                (NP (JJ:[2401..2406] human) (NN:[2407..2412] liver))))))))
    (,:[2412..2413] ,)
    (NP-SBJ-2
      (NP (DT:[2414..2417] the) (NN:[2419..2430] possibility))
      (PP (IN:[2431..2433] of)
        (NP
          (NP
            (ADJP (FW:[2434..2436] in) (FW:[2437..2441] vivo))
            (NN:[2442..2446] drug) (NNS:[2447..2459] interactions))
          (PP (IN:[2460..2462] of)
            (NP
              (NP (NN:[2463..2474] nicardipine))
              (CC:[2475..2478] and)
              (NP
                (NP (JJ:[2479..2484] other) (NNS:[2485..2490] drugs))
                (SBAR
                  (WHNP-1 (WDT:[2491..2496] which))
                  (S
                    (NP-SBJ-1 (-NONE-:[2496..2496] *T*))
                    (VP (VBP:[2498..2501] are)
                      (ADVP (RB:[2502..2508] mainly))
                      (VP (VBN:[2509..2520] metabolised)
                        (NP-1 (-NONE-:[2520..2520] *T*))
                        (PP (IN:[2521..2523] by)
                          (NP-LGS (NN:[2524..2530] CYP2C9)
                                  (CC:[2531..2537] and/or)
                                  (NN:[2538..2544] CYP3A4)))))))))))))
    (VP (VBD:[2545..2548] was)
      (VP (VBN:[2549..2558] suggested)
        (NP-2 (-NONE-:[2558..2558] *))))
    (.:[2558..2559] .)))

;sentence 21 Span:2560..2695
;The inhibition of  human CYP isoforms by 1,4-dihydropyridine calcium
;antagonists except nicardipine  might be clinically insignificant.
;[2585..2597]:cyp450:"CYP isoforms"
;[2601..2620]:substance:"1,4-dihydropyridine"
;[2621..2628]:substance:"calcium"
;[2629..2640]:substance:"antagonists"
;[2648..2659]:substance:"nicardipine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2560..2563] The) (NN:[2564..2574] inhibition))
      (PP (IN:[2575..2577] of)
        (NP (JJ:[2579..2584] human)
           (NN:[2585..2588] CYP) (NNS:[2589..2597] isoforms)))
      (PP (IN:[2598..2600] by)
        (NP
          (NP (NN:[2601..2620] 1,4-dihydropyridine) (NN:[2621..2628] calcium)
              (NNS:[2629..2640] antagonists))
          (PP (IN:[2641..2647] except)
            (NP (NN:[2648..2659] nicardipine))))))
    (VP (MD:[2661..2666] might)
      (VP (VB:[2667..2669] be)
        (ADJP-PRD (RB:[2670..2680] clinically) (JJ:[2681..2694] insignificant))))
    (.:[2694..2695] .)))

;section 22 Span:2699..2744
;PMID: 10805063 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2699..2703] PMID) (::[2703..2704] :) (CD:[2705..2713] 10805063)
        (NN:[2714..2715] -LSB-) (NNP:[2715..2721] PubMed) (::[2722..2723] -)
        (NN:[2724..2731] indexed) (IN:[2732..2735] for)
        (NNP:[2736..2744] MEDLINE-RSB-)))
